FOLH1 and prostate carcinoma: The prostate-specific membrane antigen (PSMA) was found to be overexpressed in the majority of prostate cancer cases [1,2] and is, therefore, a promising target for radionuclide therapy of metastatic castration-resistant prostate cancer (mCRPC) [3,4,5].